Medical Cannabis for Chronic Pain UK — Complete Patient Guide

What Is Chronic Pain?

Chronic pain is defined as pain lasting longer than three months — pain that persists beyond the expected period of healing or that accompanies a chronic health condition. In the UK, an estimated 28 million adults live with chronic pain, making it one of the leading causes of long-term disability and reduced quality of life. Chronic pain differs fundamentally from acute pain: rather than serving as a warning signal, it becomes a condition in its own right, reshaping the nervous system and affecting mental health, sleep, and daily function.

Conditions associated with chronic pain include neuropathic pain, fibromyalgia, osteoarthritis, rheumatoid arthritis, lower back pain, migraine, and cancer-related pain. Despite affecting millions, many patients find conventional treatments — paracetamol, NSAIDs, opioids, antidepressants — inadequate or accompanied by intolerable side effects. This is why growing numbers of UK patients are exploring medical cannabis as an alternative or adjunct therapy.

How Cannabis Works for Pain — CB1 and CB2 Receptors

The human body contains a network of receptors, enzymes, and endogenous compounds known as the endocannabinoid system (ECS). This system plays a central role in regulating pain, inflammation, mood, sleep, and immune function. The two primary receptors — CB1 and CB2 — are distributed throughout the body and respond to both endogenous cannabinoids (such as anandamide and 2-AG) and plant-derived cannabinoids (phytocannabinoids) like THC and CBD.

CB1 Receptors

CB1 receptors are concentrated in the central nervous system, particularly in areas involved in pain processing: the periaqueductal grey matter, dorsal horn of the spinal cord, thalamus, and cortex. When THC binds to CB1 receptors, it modulates the transmission of pain signals, reducing the perception of pain intensity. This is why THC-dominant cannabis preparations can provide significant relief for neuropathic and central sensitisation pain states.

CB2 Receptors

CB2 receptors are found predominantly in immune cells, peripheral nerve fibres, and inflamed tissues. CBD and certain minor cannabinoids act on CB2 receptors to reduce neuroinflammation and peripheral sensitisation — particularly relevant for arthritis, inflammatory bowel disease, and post-surgical pain. Unlike THC, CB2 activation does not produce psychoactive effects, making CBD-dominant preparations attractive for patients who wish to avoid intoxication.

Types of Chronic Pain Treated with Medical Cannabis

Neuropathic Pain

Neuropathic pain — caused by damage or dysfunction of the nervous system — responds particularly well to cannabinoid therapy. Conditions such as diabetic peripheral neuropathy, post-herpetic neuralgia, HIV-associated neuropathy, and chemotherapy-induced peripheral neuropathy have all been studied in clinical trials. A 2021 meta-analysis published in JAMA Network Open found moderate-quality evidence supporting cannabis-based medicines for neuropathic pain reduction. UK clinicians most frequently prescribe cannabis for this indication.

Fibromyalgia

Fibromyalgia is characterised by widespread musculoskeletal pain, fatigue, and cognitive difficulties ("fibro fog"). The ECS appears dysfunctional in fibromyalgia patients — some researchers propose "clinical endocannabinoid deficiency" as a contributing mechanism. Observational studies and patient surveys consistently show improvements in pain scores, sleep quality, and fatigue with medical cannabis use. High-CBD preparations with a modest THC component are commonly recommended. See our dedicated fibromyalgia guide for more detail.

Chronic Back Pain

Lower back pain is the single largest cause of disability in the UK. For patients who have failed physiotherapy, NSAIDs, and opioid therapy, medical cannabis offers a novel mechanism of action. THC reduces central sensitisation and modulates descending pain pathways, while CBD addresses the inflammatory component common in facet joint arthritis and degenerative disc disease. Many UK specialists prescribe a balanced THC:CBD oil taken nightly alongside a low-THC flower for breakthrough pain.

Arthritis

Both osteoarthritis and rheumatoid arthritis are recognised indications for medical cannabis in the UK. CB2 receptor activation in synovial tissue reduces inflammatory cytokine production, while CB1 activation modulates joint nociception. A 2020 survey by Arthritis Action found that 20% of respondents had tried cannabis for their arthritis, with the majority reporting benefit. UK clinicians typically recommend CBD-dominant preparations with low-dose THC for daytime use, reserving higher-THC products for night-time pain and sleep support.

Which Strains Help Chronic Pain?

Strain choice matters. Browse our full strain database for detailed profiles, but here is a practical overview:

Indica-Dominant Strains

Indica-dominant cultivars are associated with body-centred effects — muscle relaxation, sedation, and heavy limb sensations. They are generally preferred for evening use when pain interferes with sleep. Northern Lights, Granddaddy Purple, and OG Kush are commonly prescribed for severe chronic pain with an insomnia component.

Sativa-Dominant Strains

Sativa-dominant cultivars tend to produce more cerebral, uplifting effects and are better tolerated during the day. They can help with pain-related fatigue and mood disturbance. However, high-THC sativa preparations can worsen anxiety in sensitive patients — starting low and going slow is essential.

High-CBD / Balanced Strains

For patients who cannot tolerate THC intoxication, or who need to remain cognitively clear (e.g., for driving or work), high-CBD strains such as ACDC, Cannatonic, and Charlotte's Web derivatives provide anti-inflammatory and analgesic effects without significant psychoactivity. Balanced THC:CBD preparations (1:1) often outperform either cannabinoid alone — the so-called entourage effect.

How to Get Prescribed Medical Cannabis for Chronic Pain

In the UK, medical cannabis was legalised in November 2018. Specialist doctors can prescribe cannabis-based medicinal products (CBMPs) for chronic pain where other treatments have been inadequate. The pathway typically involves:

1. Referral to a specialist cannabis clinic (most accept self-referral)
2. Initial consultation with a GMC-registered specialist (£50–£199 depending on clinic)
3. Review of medical history and previous treatments
4. Prescription issued if clinically appropriate
5. Monthly follow-up appointments and prescription renewals

Explore our UK clinic comparison and our guide on how to get a prescription for step-by-step advice. You can also learn how to choose the right clinic.

Costs

Medical cannabis for chronic pain is not routinely funded by the NHS — patients typically pay privately. Costs vary by clinic and product:

• Initial consultation: £0–£199
• Monthly flower prescription (10–20g): £100–£250
• Monthly oil prescription: £80–£200
• Follow-up appointments: £0–£99/month

See our full cost breakdown guide and use the budget calculator to estimate your monthly spend. Comparing prices across clinics using LeafMe can save £50–£120 per month.

Expected Outcomes

Clinical experience and patient surveys suggest that 60–70% of chronic pain patients report meaningful pain reduction with medical cannabis. Most patients do not achieve complete pain relief but experience a reduction in pain intensity (typically 2–3 points on a 10-point scale), improved sleep, reduced reliance on opioids and other analgesics, and better mood. Benefits typically emerge within 2–4 weeks of starting treatment and are sustained with ongoing use. A small proportion of patients (10–15%) do not respond or experience intolerable side effects (most commonly fatigue, dizziness, or anxiety at higher THC doses).

Medical cannabis is most effective as part of a multimodal pain management strategy that includes physiotherapy, psychological support, and lifestyle modification. It is not a cure, but for many patients it provides a meaningful improvement in quality of life where other options have failed.